Blood Indices of the Patients with β-Thalassemia Minor Compared to the Patients with β-Thalassemia Minor-Alpha-Thalassemia
Abstract
Objective: Thalassemia, as one of the most common genetic diseases, is a group of hereditary hemoglobin disorders due to a slight disturbance in the production of alpha and beta globin chains in the structure of hemoglobin. There are still no clear criteria for differentiating thalassemia types based on hematological findings. In the current study, we aimed to evaluate the low-grade beta-thalassemia (β-thalassemia) indices in comparison with β-thalassemia minor with alpha-thalassemia (α-thalassemia).
Methods and Materials: In this descriptive-analytic study, 120 patients were enrolled, including 80 patients with minor β-thalassemia and 40 patients with minor β-thalassemia with α-thalassemia. Of all patients, 5cc blood samples were taken. The red blood cell parameters including mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and hemoglobin were determined. The level of MCV> 80 and A2> 3.5 β-thalassemia minor and MCV <80 and A2 <3.5 were considered as elevated thalassemia or iron deficiency anemia.
Results: The results showed that the mean of hemoglobin, HCT, MCH, MCHC, and MCV in the β-thalassemia group was significantly lower than that of the β-thalassemia with α-thalassemia group (P <0.0001). On the other hand, the level of these indices in the control group was significantly higher than in the two groups of patients (P<0.0001). The results showed that the percentage of hemoglobin A2 in the β-alpha-thalassemia group was 4.5 ± 0.91, significantly higher than the β-thalassemia group. The rate of hemoglobin and MCV was significantly lower in the β-thalassemia group compared to the silent and trait β+αthalassemia group. Also, the rate of hematocrit was significantly lower in the β-thalassemia group compared to the trait, although had no significant difference with the silence group.
Conclusion: Based on our findings, despite the difference between some hematocrit indices in the patients with β-thalassemia and β-αthalassemia, these indices cannot be used as differential indices.
2. Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, et al. Current status of beta-thalassemia and its treatment strategies. Mol Genet Genomic Med. 2021;9(12):e1788.
3. Mehdi SRAl Dahmash BA. A comparative study of hematological parameters of alpha and beta thalassemias in a high prevalence zone: Saudi Arabia. Indian J Hum Genet. 2011;17(3):207-11.
4. Kattamis A, Forni GL, Aydinok YViprakasit V. Changing patterns in the epidemiology of beta-thalassemia. Eur J Haematol. 2020;105(6):692-703.
5. Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428-42.
6. Brancaleoni V, Di Pierro E, Motta ICappellini MD. Laboratory diagnosis of thalassemia. Int J Lab Hematol. 2016;38 Suppl 1:32-40.
7. Giordano PC. Strategies for basic laboratory diagnostics of the hemoglobinopathies in multi-ethnic societies: interpretation of results and pitfalls. Int J Lab Hematol. 2013;35(5):465-79.
8. Vichinsky EP. Changing patterns of thalassemia worldwide. Ann N Y Acad Sci. 2005;1054(1):18-24.
9. Muncie HL, Jr.Campbell J. Alpha and beta thalassemia. Am Fam Physician. 2009;80(4):339-44.
10. Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P, Maggio A, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124(1):114-7.
11. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Survival and complications in thalassemia. Ann N Y Acad Sci. 2005;1054(1):40-7.
12. Khatami S, Rouhi Dehboneh S, Sadeghi S, Saeidi P, Mirzazadeh R, Bayat P, et al. Globin chain synthesis for Differential diagnosis of β thalassemia from α thalassemia carriers. Scientific Journal of Iran Blood Transfus Organ. 2008;4(4):239-46.
13. Mach-Pascual S, Darbellay R, Pilotto PABeris P. Investigation of microcytosis: a comprehensive approach. Eur J Haematol. 1996;57(1):54-61.
14. Joola P, Andashti B, Hosseini SA, Zadeh SMMBahrami N. The frequency of beta-thalassemia mutations among carriers in Dezful city, southwest Iran. Iranian Journal of Public Health. 2020;49(12):2438.
15. Dehghanifard A, Shahjahani M, Galehdari H, Rahim F, Hamid F, Jaseb K, et al. Prenatal Diagnosis of Different Polymorphisms of beta-globin Gene in Ahvaz. Int J Hematol Oncol Stem Cell Res. 2013;7(2):17-22.
16. Fowkes FJ, Allen SJ, Allen A, Alpers MP, Weatherall DJDay KP. Increased microerythrocyte count in homozygous alpha(+)-thalassaemia contributes to protection against severe malarial anaemia. PLoS Med. 2008;5(3):e56.
17. Balgir RS. Hematological profile of twenty-nine tribal compound cases of hemoglobinopathies and G-6-PD deficiency in rural Orissa. Indian J Med Sci. 2008;62(9):362-71.
18. Alhamdan NA, Almazrou YY, Alswaidi FMChoudhry AJ. Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genet Med. 2007;9(6):372-7.
19. Al-Awamy BH. Thalassemia syndromes in Saudi Arabia. Meta-analysis of local studies. Saudi Med J. 2000;21(1):8-17.
20. Sivera P, Roetto A, Mazza UCamaschella C. Feasibility of molecular diagnosis of alpha-thalassemia in the evaluation of microcytosis. Haematologica. 1997;82(5):592-3.
| Files | ||
| Issue | Vol 5, No 2 (2022) | |
| Section | Original Article | |
| DOI | https://doi.org/10.18502/igj.v5i2.15098 | |
| Keywords | ||
| Β-Thalassemia β-α-Thalassemia Mean Corpuscular Volume (MCV) Mean Corpuscular He- moglobin (MCH) | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
